We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A late-stage study of Sanofi and Regeneron’s Dupixent in adolescents with atopic dermatitis has met its key targets, paving the way for a regulatory submission for drug targeting this younger patient group in the third quarter.